Cara Therapeutics (CARA) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cara Therapeutics Reports Second Quarter 2016 Financial Results
August 4, 2016 4:02 PM EDTResumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative painÂ
Initiated adaptive Phase 2/3 trial for I.V. CR845 in dialysis patients with uremic pruritusÂ
Initiation of Phase 2b trial of Oral CR845 in osteoarthritis patients expected in Q3, 2016
Conference call today at 4:30 p.m. ET
STAMFORD, Conn., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively... More
